AU2001239791A1 - Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production - Google Patents

Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production

Info

Publication number: AU2001239791A1
Authority: AU; Australia
Prior art keywords: succinoylamino; carbocycles; heterocycles; inhibitors; protein production
Prior art date: 2000-02-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Thomas P. MADUSKUIE JR.

Richard E. Olson

Andrew J. Tebben

Lorin Andrew Thompson

Nenghui Wang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Pharma Co

Original Assignee

DuPont Merck Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-16Application filed by DuPont Merck Pharmaceutical CofiledCriticalDuPont Merck Pharmaceutical Co

2001-08-27Publication of AU2001239791A1publicationCriticalpatent/AU2001239791A1/en

StatusAbandonedlegal-statusCriticalCurrent

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Psychiatry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AU2001239791A2000-02-172001-02-16Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein productionAbandonedAU2001239791A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US18318600P	2000-02-17	2000-02-17
US60183186		2000-02-17
PCT/US2001/005236WO2001060826A2 (en)	2000-02-17	2001-02-16	SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION

Publications (1)

Publication Number	Publication Date
AU2001239791A1true AU2001239791A1 (en)	2001-08-27

Family

ID=22671796

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001239791AAbandonedAU2001239791A1 (en)	2000-02-17	2001-02-16	Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production

Country Status (6)

Country	Link
US (1)	US6525044B2 (en)
EP (1)	EP1261610A2 (en)
JP (1)	JP2003523345A (en)
AU (1)	AU2001239791A1 (en)
CA (1)	CA2395862A1 (en)
WO (1)	WO2001060826A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP990246A2 (en)	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en)	1998-08-07	2004-09-24	Pont Pharmaceuticals Du	Succinoylamino lactams as inhibitors of Abeta protein production
EP1313426A2 (en)	1998-12-24	2003-05-28	Bristol-Myers Squibb Pharma Company	Succinoylamino benzodiazepines as inhibitors of a-beta protein production
CA2395862A1 (en)	2000-02-17	2001-08-23	Hong Liu	Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production
MXPA02009755A (en)	2000-04-03	2003-03-27	Bristol Myers Squibb Pharma Co	CYCLIC LACTAMS AS INHIBITORS OF Abeta PROTEIN PRODUCTION.
MXPA02009729A (en)	2000-04-03	2003-03-27	Bristol Myers Squibb Pharma Co	CYCLIC LACTAMS AS INHIBITORS OF A beta PROTEIN PRODUCTION.
US7640062B2 (en)	2000-05-08	2009-12-29	Brainsgate Ltd.	Methods and systems for management of alzheimer's disease
US7146209B2 (en)*	2000-05-08	2006-12-05	Brainsgate, Ltd.	Stimulation for treating eye pathologies
AU2001261728A1 (en)	2000-05-17	2001-11-26	Bristol-Myers Squibb Pharma Company	Use of small molecule radioligands for diagnostic imaging
BR0106717A (en)	2000-06-01	2002-04-16	Bristol Myers Squibb Pharma Co	Compounds, pharmaceutical composition and uses of innovative lactam compounds
EP1466898A4 (en)*	2001-12-27	2005-12-07	Daiichi Seiyaku Co	Beta-amyloid protein production/secretion inhibitors
US7684859B2 (en)*	2002-04-25	2010-03-23	Brainsgate Ltd.	Stimulation of the OTIC ganglion for treating medical conditions
JP2006500318A (en)*	2002-04-25	2006-01-05	ブレインスゲートリミテッド	Method and apparatus for adjusting the characteristics of BBB and cerebral circulation using nerve excitatory and / or neurosuppressive effects of odorants on the intracranial nerve
EP1585430B1 (en)*	2002-11-14	2017-01-11	Brainsgate Ltd.	Surgical tools and techniques for stimulation
US8055347B2 (en)	2005-08-19	2011-11-08	Brainsgate Ltd.	Stimulation for treating brain events and other conditions
US8010189B2 (en)*	2004-02-20	2011-08-30	Brainsgate Ltd.	SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en)	2004-02-20	2016-01-12	Brainsgate Ltd.	SPG stimulation
WO2006021957A2 (en)*	2004-08-23	2006-03-02	Brainsgate Ltd.	Concurrent bilateral spg modulation
EP1966169A2 (en)*	2005-12-29	2008-09-10	Immupharma France SA	Compositions and methods for the inhibition of phospholipase a2
CA2635359A1 (en)*	2005-12-29	2007-07-05	Immupharma France Sa	Compositions and methods for synthesizing heterocyclic therapeutic compounds
US20090210026A1 (en)*	2006-08-17	2009-08-20	Brainsgate Ltd.	Spg stimulation for enhancing neurogenesis and brain metabolism
US20100204230A1 (en)	2007-02-12	2010-08-12	Peter Blurton	Piperazine derivatives for treatment of ad and related conditions
CN101284828B (en)*	2007-04-12	2011-04-27	中国科学院上海药物研究所	Cycloheptanepyridine compounds, their preparation method, use and pharmaceutical composition containing such compounds
US7860569B2 (en)	2007-10-18	2010-12-28	Brainsgate, Ltd.	Long-term SPG stimulation therapy for prevention of vascular dementia
CN101945853B (en)	2007-12-21	2014-08-20	配体药物公司	Selective androgen receptor modulators (sarms) and uses thereof
EP2291181B9 (en)	2008-04-18	2013-09-11	University College Dublin National University Of Ireland, Dublin	Captodiamine for the treatment of depression symptoms
CA2767764A1 (en)	2009-07-13	2011-01-20	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
CN103249733A (en)	2010-09-02	2013-08-14	武田药品工业株式会社	Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
TWI530489B (en)	2011-03-22	2016-04-21	必治妥美雅史谷比公司	Bis(fluoroalkyl)-1,4-benzodiazepine compound
GB201116559D0 (en)	2011-09-26	2011-11-09	Univ Leuven Kath	Novel viral replication inhibitors
US9242941B2 (en)	2012-09-21	2016-01-26	Bristol-Myers Squibb Company	Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
US9242940B2 (en)	2012-09-21	2016-01-26	Bristol-Myers Squibb Company	N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
US9427442B2 (en)	2012-09-21	2016-08-30	Bristol-Myers Squibb Company	Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds
EP2897944B1 (en)*	2012-09-21	2016-10-26	Bristol-Myers Squibb Company	Substituted 1,5-benzodiazepinone compounds
JP2015529250A (en)	2012-09-21	2015-10-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Fluoroalkyldibenzodiazepinone compounds
TWI614238B (en)*	2012-09-21	2018-02-11	必治妥美雅史谷比公司	Bis(fluoroalkyl)-1,4-benzodiazepine compounds and prodrugs thereof
JP2015529251A (en)	2012-09-21	2015-10-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Tricyclic heterocyclic compounds as NOTCH inhibitors
JP2015531792A (en)	2012-09-21	2015-11-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Prodrugs of 1,4-benzodiazepinone compounds
WO2014047392A1 (en)	2012-09-21	2014-03-27	Bristol-Myers Squibb Company	Fluoroalkyl-1,4-benzodiazepinone compounds
EP2981267A1 (en)	2013-04-04	2016-02-10	Bristol-Myers Squibb Company	Combination therapy for the treatment of proliferative diseases
US9675796B2 (en)	2013-11-10	2017-06-13	Brainsgate Ltd.	Implant and delivery system for neural stimulator
US10441567B2 (en)	2014-01-17	2019-10-15	Ligand Pharmaceuticals Incorporated	Methods and compositions for modulating hormone levels
US10271907B2 (en)	2015-05-13	2019-04-30	Brainsgate Ltd.	Implant and delivery system for neural stimulator
JP2022529341A (en)	2019-04-19	2022-06-21	リガンド・ファーマシューティカルズ・インコーポレイテッド	The crystalline form of the compound and the method for producing the crystalline form of the compound.

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2630440B1 (en)*	1988-04-25	1991-09-20	Jouveinal Sa	BENZODIAZEPINES, THEIR PREPARATION PROCESS AND INTERMEDIATES AND THEIR THERAPEUTIC APPLICATIONS
EP0411668B2 (en)	1989-08-04	1998-11-11	MERCK SHARP & DOHME LTD.	Central cholecystokinin antagonists for treatment of psychiatric disorders
CA2026856A1 (en)	1989-10-05	1991-04-06	Mark G. Bock	3-substituted-1,4-benzodiazepines useful as oxytocin
CA2032427A1 (en)	1989-12-18	1991-06-19	Mark G. Bock	Benzodiazepines analogs
GB9107368D0 (en)	1991-04-08	1991-05-22	Smithkline Beecham Plc	Novel compounds
JP3457312B2 (en)	1992-07-29	2003-10-14	メルクシヤープエンドドームリミテツド	Benzodiasepine derivative
US5283241A (en)	1992-08-28	1994-02-01	Merck & Co., Inc.	Benzo-fused lactams promote release of growth hormone
CN1041921C (en)	1992-12-21	1999-02-03	史密丝克莱恩比彻姆公司	bicyclic fibrinogen antagonist
MX9308016A (en)	1992-12-22	1994-08-31	Lilly Co Eli	HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITING COMPOUNDS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING THEM.
CA2160786A1 (en)	1993-05-14	1994-11-24	James C. Marsters, Jr.	Ras farnesyl transferase inhibitors
AU7102394A (en)	1993-06-09	1995-01-03	Smithkline Beecham Corporation	Bicyclic fibrinogen antagonists
US5602156A (en)	1993-09-17	1997-02-11	The United States Of America As Represented By The Department Of Health And Human Services	Method for inhibiting metalloproteinase expression
US5545735A (en)	1993-10-04	1996-08-13	Merck & Co., Inc.	Benzo-Fused Lactams promote release of growth hormone
US5426185A (en)	1993-11-22	1995-06-20	Merck & Co., Inc.	Antiarrhythmic benzodiazepines
US5770573A (en)	1993-12-06	1998-06-23	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
CA2196062A1 (en)	1994-07-29	1996-02-15	Yoshinari Sato	Benzodiazepine derivatives
US5661161A (en)	1994-09-29	1997-08-26	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
JPH11505509A (en)	1994-12-09	1999-05-21	スミスクライン・ビーチャム・コーポレイション	Bicyclic fibrinogen antagonist
US5639746A (en)	1994-12-29	1997-06-17	The Procter & Gamble Company	Hydroxamic acid-containing inhibitors of matrix metalloproteases
WO1996018602A1 (en)	1994-12-13	1996-06-20	Smithkline Beecham Corporation	Bicyclic fibrinogen antagonists
US5672598A (en)*	1995-03-21	1997-09-30	The Procter & Gamble Company	Lactam-containing hydroxamic acids
US5856326A (en)	1995-03-29	1999-01-05	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5578629A (en)	1995-03-29	1996-11-26	Merck & Co., Inc.	Benzamide-containing inhibitors of farnesyl-protein transferase
GB9507799D0 (en)	1995-04-18	1995-05-31	British Biotech Pharm	Metalloproteinase inhibitors
US5710171A (en)	1995-05-24	1998-01-20	Merck & Co., Inc.	Bisphenyl inhibitors of farnesyl-protein transferase
EP0828754B1 (en)	1995-05-29	2005-02-02	Pfizer Inc.	Dipeptides which promote release of growth hormone
US5756528A (en)	1995-06-06	1998-05-26	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
EP0761680A3 (en)	1995-09-12	1999-05-06	Ono Pharmaceutical Co., Ltd.	Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
AU7139996A (en)	1995-10-05	1997-04-28	Chiroscience Limited	Mercaptoamide derivatives and their therapeutic use
WO1997019053A1 (en)	1995-11-23	1997-05-29	British Biotech Pharmaceuticals Limited	Metalloproteinase inhibitors
JP2000504014A (en)	1996-01-30	2000-04-04	メルクエンドカンパニーインコーポレーテッド	Farnesyl-protein transferase inhibitor
US5891889A (en)	1996-04-03	1999-04-06	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5919785A (en)	1996-04-03	1999-07-06	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU715603B2 (en)	1996-04-03	2000-02-03	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5965578A (en)	1996-04-03	1999-10-12	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5885995A (en)	1996-04-03	1999-03-23	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5869682A (en)	1996-04-03	1999-02-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5859012A (en)	1996-04-03	1999-01-12	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU2555997A (en)	1996-04-03	1997-10-22	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5852010A (en)	1996-04-03	1998-12-22	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
CA2250460A1 (en)	1996-04-03	1997-10-09	John H. Hutchinson	Inhibitors of farnesyl-protein transferase
CA2251955A1 (en)	1996-04-18	1997-10-23	Nancy E. Kohl	A method of treating cancer
EP0934270A1 (en)	1996-05-30	1999-08-11	Merck & Co., Inc.	A method of treating cancer
US5703129A (en)	1996-09-30	1997-12-30	Bristol-Myers Squibb Company	5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
JP2001504810A (en)	1996-10-11	2001-04-10	シーオーアール・セラピューティックス・インコーポレーテッド	Selective factor Xa inhibitor
PL323130A1 (en)	1996-11-15	1998-05-25	Hoechst Ag	Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
ATE296797T1 (en)	1996-11-22	2005-06-15	Elan Pharm Inc	N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS THEREFOR, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE OR SYNTHESIS
IL129238A0 (en)	1996-11-22	2000-02-17	Elan Pharm Inc	N-(aryl/heteroarylacetyl) amino acid esters pharmaceutical compositions comprising same and methods for inhibiting b-amyloid peptide release and/ or its synthesis by use of such compounds
NZ335157A (en)	1996-11-22	2001-01-26	Elan Pharm Inc	N-(aryl/heteroaryl) amino acid derivatives and methods for inhibiting beta-amyloid peptide release or its synthesis
AU5585198A (en)	1996-11-22	1998-06-10	Athena Pharmaceuticals, Inc.	N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and ethods for inhibiting beta-amyloid peptide release and/or its synthesis
TW523506B (en)	1996-12-18	2003-03-11	Ono Pharmaceutical Co	Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
EA002100B1 (en)*	1996-12-23	2001-12-24	Элан Фармасьютикалз, Инк.	CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHOD FOR INHIBITING beta-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESISBY USE OF SUCH COMPOUNDS
CA2276081A1 (en)	1996-12-30	1998-07-09	Lekhanh O. Tran	Inhibitors of farnesyl-protein transferase
EP0968206B8 (en)	1997-02-19	2007-01-24	Berlex, Inc.	N-heterocyclic derivatives as nos inhibitors
WO1998041510A1 (en)	1997-03-14	1998-09-24	Shionogi & Co., Ltd.	Novel benzolactam derivatives and medicinal compositions comprising the same
US5985900A (en)*	1997-04-01	1999-11-16	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EP0973396A4 (en)	1997-04-07	2001-02-07	Merck & Co Inc	A method of treating cancer
US6060038A (en)	1997-05-15	2000-05-09	Merck & Co., Inc.	Radiolabeled farnesyl-protein transferase inhibitors
DE19726427A1 (en)	1997-06-23	1998-12-24	Boehringer Mannheim Gmbh	Pyrimidine-2,4,6-trione derivatives, processes for their preparation and medicaments containing these compounds
GB9715030D0 (en)	1997-07-18	1997-09-24	British Biotech Pharm	Metalloproteinase inhibitors
JP2001515842A (en)	1997-08-11	2001-09-25	シーオーアールセラピューティクスインコーポレイテッド	Selective factor Xa inhibitor
ATE211482T1 (en)	1997-08-11	2002-01-15	Cor Therapeutics Inc	SELECTIVE INHIBITORS OF FACTOR X CONTAINING AN AZEPINE STRUCTURE
AU735366B2 (en)	1997-09-29	2001-07-05	Bristol-Myers Squibb Company	Inhibitors of farnesyl protein transferase
US6297239B1 (en)	1997-10-08	2001-10-02	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
US6440965B1 (en)	1997-10-15	2002-08-27	Krenitsky Pharmaceuticals, Inc.	Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
AU1277799A (en)*	1997-12-22	1999-07-12	Elan Pharmaceuticals, Inc.	Polycyclic alpha-amino-$m(e)-caprolactams and related compounds
NZ505800A (en)	1998-02-20	2002-09-27	Deep Video Imaging Ltd	A multi-layer display and a method for extracting depth from 2D video data
PA8469501A1 (en)*	1998-04-10	2000-09-29	Pfizer Prod Inc	HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
AU5204799A (en)	1998-06-22	2000-01-10	Elan Pharmaceuticals, Inc.	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
CA2324475A1 (en)	1998-06-22	1999-12-29	Elan Pharmaceuticals, Inc.	Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
WO1999067221A1 (en)	1998-06-22	1999-12-29	Elan Pharmaceuticals, Inc.	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
EP1089977A1 (en)	1998-06-22	2001-04-11	Elan Pharmaceuticals, Inc.	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO2000002903A1 (en)*	1998-07-10	2000-01-20	Cytel Corporation	Cs-1 peptidomimetics, compositions and methods of using the same
HRP990246A2 (en)	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
AU1618000A (en)	1998-11-12	2000-05-29	Du Pont Pharmaceuticals Company	Use of radioligands to screen inhibitors of amyloid-beta peptide production
EP1313426A2 (en)	1998-12-24	2003-05-28	Bristol-Myers Squibb Pharma Company	Succinoylamino benzodiazepines as inhibitors of a-beta protein production
CA2395862A1 (en)	2000-02-17	2001-08-23	Hong Liu	Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production

2001
- 2001-02-16CACA002395862Apatent/CA2395862A1/ennot_activeAbandoned
- 2001-02-16AUAU2001239791Apatent/AU2001239791A1/ennot_activeAbandoned
- 2001-02-16EPEP01914400Apatent/EP1261610A2/ennot_activeWithdrawn
- 2001-02-16WOPCT/US2001/005236patent/WO2001060826A2/ennot_activeApplication Discontinuation
- 2001-02-16USUS09/788,227patent/US6525044B2/ennot_activeExpired - Lifetime
- 2001-02-16JPJP2001560210Apatent/JP2003523345A/enactivePending

Also Published As

Publication number	Publication date
US20020055501A1 (en)	2002-05-09
JP2003523345A (en)	2003-08-05
EP1261610A2 (en)	2002-12-04
WO2001060826A2 (en)	2001-08-23
CA2395862A1 (en)	2001-08-23
US6525044B2 (en)	2003-02-25
WO2001060826A3 (en)	2002-01-17

Publication	Publication Date	Title
AU2001239791A1 (en)	2001-08-27	Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production
AU2001257006A1 (en)	2001-10-23	Substituted lactams as inhibitors of abeta protein production
AU7997600A (en)	2001-04-23	Amino lactam sulfonamides as inhibitors of abeta protein production
AU2002213485A1 (en)	2002-04-22	Inhibitors of protein kinases
AU2002256418A1 (en)	2002-11-11	Inhibitors of bace
AU2002316137A1 (en)	2002-12-03	Method of determining protein interaction inhibitors
AU2002331311A1 (en)	2003-04-01	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
AU2002324468A1 (en)	2003-03-03	Rapid improvement of cognition in conditions related to abeta
AU2002367147A1 (en)	2003-07-15	Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
AU2003211093A1 (en)	2003-09-09	Inhibitors of rgs proteins
AU2002330453A1 (en)	2003-06-05	Crystals of hydroxynorephedrine derivative
AU2001275530A1 (en)	2001-12-17	Inhibitors of c-reactive protein induced inflammation
AU2002306624A1 (en)	2002-09-19	Heterocyclic analgesic compounds and methods of use thereof
AU2001244692A1 (en)	2001-12-20	Novel crystal form of pyrrolidylthiocarbapenem derivative
AU2002214286A1 (en)	2002-05-27	Method of profiling protein
AU2002337913A1 (en)	2003-04-28	Glycosulfopeptide inhibitors and methods of use thereof
AU2002238103A1 (en)	2002-08-28	Use of beta-lactamase inhibitors as neuroprotectants
AU2002338734A1 (en)	2003-07-03	Use of phosphorodiesterase IV inhibitors
AU1929301A (en)	2001-06-04	Methods of use of peptide deformylase inhibitors as novel antibacterial agents
AU2003295638A1 (en)	2004-06-18	NOVEL INHIBITORS OF Beta-LACTAMASE
AU2003258941A1 (en)	2004-04-30	Metalloproteinase inhibitors and intermediates for preparation thereof
AU2001249477A1 (en)	2001-10-08	Lactams as inhibitors of a-beta protein production
AU2002305868A1 (en)	2002-12-23	Inhibitors of reggamma
AU2002354363A1 (en)	2003-06-17	Method of activating protein
AU4021700A (en)	2000-10-09	Methods of use of beta1-integrin inhibitors

Movatterモバイル変換

AU2001239791A1 - Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=22671796

Family Applications (1)

Country Status (6)

Families Citing this family (44)

Family Cites Families (77)

Also Published As

Similar Documents